Marilyn Schapira, MD, MPH, offers an overview of the oncology genomic testing program at the Center for Personalized Diagnostics at Penn Medicine, which includes comprehensive heme-NGS and solid tumor panels for somatic mutations in AML, brain tumors, GI malignancies, lung malignancies, and melanoma. Dr. Schapira’s discussion also delves into the factors that influence the uptake of CPD testing and treatment decisions among physicians who use the CPD.
Related Links
Published
October 14, 2013
Created by
BROADCASTMED